Clinical Trial Update: A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects [Phase 2]

View source ↗

Summary

Pfizer's Phase 2 study of PF-00610355 in moderately asthmatic subjects has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Bronchitis
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• PF-00610355

Snippet

Sponsor: Pfizer | Conditions: Asthma, Bronchial, Lung Diseases, Obstructive | Phase 2 | Status: WITHDRAWN